AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Purpose

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Conditions

  • Epilepsy
  • Seizure

Eligibility

Eligible Ages
Between 14 Years and 24 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed with epilepsy - Currently prescribed anti-seizure medicine (ASMs) - Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) - Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study - Are between 18-24 years old and able to provide informed consent - Able to read, speak, and write in English - Resides in Florida - Receive outpatient medical services

Exclusion Criteria

  • They do not own a mobile device with internet access. - They have a history of severe intellectual disability. - They are unable to operate a mobile device (keyboard or touchscreen). - Reside in an in-patient setting. - Adults unable to consent. - Pregnant women (excluded because pregnancy is not relevant to the study focus). - Prisoners.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Supportive Care
Masking
Single (Participant)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Medilepsy® Chatbot AI-Enhanced 		Participants in the intervention group will use the AI-personalized version of the Medilepsy® app.
  • Other: Medilepsy® Chatbot AI-Enhanced
    Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.
Active Comparator
Medilepsy® Chatbot Standard 		Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality.
  • Other: Medilepsy® Chatbot Standard
    Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.

Recruiting Locations

Orlando Health
Orlando, Florida 32806
Contact:
Michelle Tall, PhD, RN, FAES

University of Central Florida
Orlando, Florida 32827
Contact:
Amoy Fraser, PhD, CCRP, PMP
4072668742
Amoy.Fraser@ucf.edu

More Details

Status
Recruiting
Sponsor
University of Central Florida

Study Contact

Michelle Tall, PhD, RN, FAES
4077970555
Michelle.Tall@UCF.edu